Weekly Recap: Northstar reimbursement +29% and CMS 15% lab fee cuts

BillionToOne, Inc. Class A (NASDAQ:BLLN) saw Northstar Response test reimbursement jump 29% to $2,124, but looming MolDx coverage decisions and CMS’s phased lab fee cuts—capped at about 15% annually through 2029—could pressure future Medicare reimbursement for the company.Previous Week RecapThis is…